Status:
COMPLETED
Phase II Dose Titration Study in Patients With Neuropathic Pain
Lead Sponsor:
Newron Pharmaceuticals SPA
Conditions:
Neuropathic Pain
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to examine the effects of various increasing doses of Ralfinamide in patients with neuropathic pain.
Eligibility Criteria
Inclusion
- Male or female patients
- Females post-menopausal for at least 12 months, 24 months in India, Poland, and Austria
- Diagnosed by neurologist with current neuropathic pain
Exclusion
- See inclusion criteria
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
272 Patients enrolled
Trial Details
Trial ID
NCT00736151
Start Date
May 1 2004
Last Update
August 7 2009
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitatsklinik Fur Neurologie
Graz, Austria
2
Universitatsklinik Fur Neurologie
Innsbruck, Austria
3
LKH
Klagenfurt, Austria
4
General Hospital AKH
Vienna, Austria